Videos
Extended Dosing of Xevinapant Post-Radiotherapy Improved Efficacy in Preclinical Models of Head and Neck Cancer
Preclinical Study of First-in-Class IAP Inhibitor
Preclinical Study of First-in-Class IAP Inhibitor
Featuring Tsz Lun Yeung, MD
07/18/2023
At the 2023 ASCO Annual Meeting, Tsz Lun Yeung, MD, EMD Serano, Inc, presented data which found extended dosing with the IAP inhibitor xevanipant improved the efficacy of radiotherapy in preclinical models of head and neck squamous cell carcinoma.
Transcript:
Source:
Yeung TL, Jiang F, Qi J, et al. Effect of extended treatment of IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models. Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract #6027